# Table 3 Functional outcome and postoperative complications in all three groups

Control group TXA 250 mg TXA 500 mg p-value
(n = 45) (n = 45) (n = 45)
WOMAC score
3 months 36.7 (8.2)** 35.8 (7.6)** 35.5 (7.2)** 0.42
6 months 25.4 (6.0)** 23.1 (6.5)** 23.5 (6.6)**
1 year 15.5 (6.6)** 15.1 (6.2)** 14.5 (7.1)**
p-value within group < 0.001** < 0.001** < 0.001**
Knee society knee score
3 months 121.7 (10.2)** 121.1 (10.1)** 123.3 (9.1)** 0.91
6 months 141.0 (11.5)** 141.2 (9.4)** 140.0 (8.9)**
1 year 148.9 (10.1)** 151.2 (9.1)** 150.9 (9.3)**
p-value within group < 0.001** < 0.001** < 0.001**
Complications
Re-clamp 6 (13%) 1 (2%) 0 (0%)*b 0.01
Re-dressing 3 (7%) 0 (0%)*a 0 (0%)*b 0.05
VTE 4 (9%) 1 (2%) 2 (4%) 0.35
Congestive heart failure 0 (0%) 1 (2%) 0 (0%) 1.00
1. ✝ = The values were presented as mean (standard deviation),  = The values were presented as number of patients having that condition (percentage of this group), **; p-value between time < 0.001, *; p < 0.05.
2. a = comparison between control and TXA-250 group with p < 0.05.
3. b = comparison between control and TXA-500 group with p < 0.05.